Subscribe now! Get as
Glenmark Pharma nasal spray given to adult Covid-19 patients showed 94% relief in viral load within 24 hours and 99% in 48 hours, based on the effects of the Phase 3 trial in The Lancet.
Nitric oxide nasal spray (NONS) is designed to kill the Sars-Cov-2 virus, which causes Covid, in the airways. When sprayed on the nasal mucosa, it acts as a physical and chemical barrier opposite to the virus and prevents it. of incubating and spreading to the lungs, the company said.
The study was conducted by Glenmark in 306 vaccinated and unvaccinated adults with mild symptomatic COVID-19, at 20 clinical centers in India. He took delta and omicron position increases.
The phase 3 double-blind clinical trial evaluated a seven-day treatment of NONS plus popular care compared to a placebo nasal spray plus popular care in patients with symptomatic COVID-19, the company said.
“The physically powerful double-blind trial demonstrated significant efficacy and remarkable protection of NONS. This treatment has the potential to contribute to the control of Covid-19, thanks to its ease of use in the existing highly transmissible phase of the pandemic. ” said Monika Tandon, Senior Vice President and Head of Clinical Development, Glenmark Pharmaceuticals Ltd.
Glenmark introduced the nasal spray with the fabiSpray logo in February this year, after receiving production and marketing approval from the Comptroller General of Medicines of India.
Customize your News Feed. Follow current issues